Search the Community
Showing results for tags 'leads'.
Found 3 results
Celiac.com 07/22/2016 - You think you have a crazy celiac disease diagnosis story? Try this one. When a college student fell and struck his shoulder while showering, he went to the emergency treatment center. There, in addition to shoulder pain from the fall, he complained of numbness in his feet, along with general weakness and fatigue in the preceding few weeks. Blood tests showed the man had mild anemia, prompting the doctor to check his vitamin B-12 level, which was also low. This was puzzling. The patient was a 20-year-old, seemingly healthy Asian man, whose omnivorous diet should have provided enough B-12 to sustain normal blood levels. That meant that the next likely cause was poor B-12 absorption through the stomach or intestines. Besides pernicious anemia, which is marked by the absence of a protein in the stomach, the most frequent causes of B-12 malabsorption include celiac disease, HIV, chronic inflammation of the pancreas and even a type of tapeworm infection. The man's youth and general good health seems to rule out pernicious anemia. Although he had adhered to a more typical Chinese diet that was heavy on fish and rice, he had recently been eating a lot of pizza. Pizza means gluten. Lots of gluten. So could he have celiac disease? Although most commonly associated with some sort of gastrointestinal distress, such as diarrhea or abdominal cramping, celiac disease can have other symptoms, such as fatigue and numbness of extremities. Celiac often interferes with the gut's ability to absorb vitamin B-12. Ultimately, the patient met with a gastroenterologist who diagnosed celiac disease. The patient saw his B-12 levels return to normal when he began a gluten-free diet. The numbness has also improved. So, remember, celiac disease can have some vague and confusing symptoms that will usually improve significantly with a gluten-free diet. Have a wild celiac disease diagnosis story of your own? Source: dispatch.com
Celiac.com 05/02/2009 - Jesse James, the low-key celebrity biker and husband of star Sondra Bullock, led a gluten-free rally to survive yet another Donald Trump challenge on the Celebrity Apprentice recently. The second task of the night on the April 19th show was to devise a new dish along with a marketing campaign for the Schwan's frozen food LiveSmart line. Facing possible elimination of a team-member, the team led by Jesse James rallied with a gluten free noodle dish to stay alive for the May 10th final. The challenge to create and market Schwan's new dish saw Jesse James running the show at Athena. Jesse chose to keep teammate Melissa with him and put colleagues Brande and Annie to work in the kitchen. Jesse led the charge with a with the turkey meatball and gluten-free pasta suggested by team member and poker champ Annie Duke, leaving himself just enough room to put it on her had it failed. The meal features meatballs made with ground turkey breast meat and a touch of pork, and seasoned with onion, mushroom, garlic, spinach, basil. The meatballs are served up on a bed of Quinoa rotelle pasta and topped with a classic tomato basil sauce. A serving of tender 100% Grade A broccoli completes the meal. Now, Jesse's reticence regarding marketing nearly saw the team's effort fail, but the meal was solid and the execution went well. So when it came time to make a cut, Trump looked to the opposition's Herschel Walker, who had twice failed in his managerial duties. Check out the gluten-free Triple Play Turkey Meatballs and Pasta Dinner featured on the Celebrity Apprentice. Sources: Schwan's Examiner.com Zap2it Popwatch
Celiac.com 02/25/2005 - Today a team of scientists at Alba Therapeutics Corporation and the University of Maryland School of Medicine report a direct link between zonulin-mediated increased intestinal permeability and Type 1 Diabetes (T1D) in the BB/wor Rat Model of Diabetes. Even more remarkable, the investigators were able to successfully prevent the onset of the autoimmune destruction of pancreatic beta cells and the onset of T1D in these animals by using the specific zonulin blocker AT-1001. Daily, oral administration of the drug beginning before the onset of auto-immunity in the diabetic prone rats cut the incidence of the disease by 2/3, and completely blocked the development of autoimmune antibodies in the treatment responders. Published in the latest issue of the Proceedings of the National Academy of Science (PNAS), these results constitute the first successful result in preventing the autoimmune process characteristic of T1D by blocking the zonulin-mediated abnormal intestinal permeability. These results go well beyond the development of a prevention strategy for T1D, says Dr. Alessio Fasano, lead author of the paper and Professor of Pediatrics, Medicine and Physiology and The University of Maryland School of Medicine. They open a new field of investigation in which the interplay between host and environment at the mucosal level may help us understanding the molecular basis of many diseases. These results reinforce our conviction that the zonulin pathway provides a roadmap for the discovery and development of innovative products to treat many important diseases, including diabetes, in ways previously thought to be inconceivable stated Dr. Blake M. Paterson. These preclinical proof-of-concept results with AT-1001 support the salvaging of beta cell function in pre-diabetics or in new-onset diabetes, giving us the impetus to rapidly move through the development process, bringing this dream to a reality for treatment in the diabetes community. T1D is an autoimmune disease that results in the destruction of the insulin producing cells of the pancreas, the islet beta cells. Current treatment of T1D is limited to the administration of insulin and other medications to treat the consequence of diabetes, elevated blood sugar and the complications thereof. The inability to treat the cause of T1D - a process known as autoimmunity, in which the bodys immune system attacks the beta cells of the pancreas - has been the key obstacle to the freeing patients from the yoke of this disease. Autoimmune diseases are thought to occur in individuals with the genetic pre-disposition to attack and destroy various organ tissues by the bodys own immune system. This immune misrecognition is thought to be triggered by the presence of an environmental stimulus; in the case of T1D, the trigger is unknown. While the majority of research efforts have focused on identifying the trigger of T1D and modifying immune pathways, little is known about how such a trigger might enter the body and about how such an entry-way might serve as a target for the treatment of the disease. The discovery of zonulin - a gatekeeper of intestinal barrier function, and its involvement in celiac disease, led to the hypothesis that its malfunction could be involved in a series of other autoimmune diseases characterized by a leaky gut, including T1D. Previous work by Dr. Alessio Fasano has shown a close association of celiac disease in children at risk of developing T1D and led to the novel discovery research in support of AT-1001. About Alba: Alba Therapeutics is a Baltimore based biopharmaceutical company dedicated to commercializing disease-modifying therapeutics and drug delivery adjuvants based on the zonulin pathway. Albas lead molecule, AT-1001, is targeted towards the treatment of Celiac Disease and Type 1 Diabetes and is in the final stages of pre-human testing. Contact Alba Therapeutics Corporation, Baltimore Dr. Blake Paterson, 410-522-8708